Jérôme Durivault

1.9k total citations
35 papers, 1.4k citations indexed

About

Jérôme Durivault is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jérôme Durivault has authored 35 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 11 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jérôme Durivault's work include Epigenetics and DNA Methylation (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Ferroptosis and cancer prognosis (6 papers). Jérôme Durivault is often cited by papers focused on Epigenetics and DNA Methylation (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Ferroptosis and cancer prognosis (6 papers). Jérôme Durivault collaborates with scholars based in France, Monaco and United States. Jérôme Durivault's co-authors include Jacques Pouysségur, Scott K. Parks, Milica Vučetić, Yann Cormerais, Éric Tambutté, Maša Ždralević, Sandy Giuliano, Valérie Vial, Hitoshi Endou and Michael F. Wempe and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

Jérôme Durivault

35 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jérôme Durivault France 17 977 638 297 246 202 35 1.4k
Niantao Deng Australia 18 968 1.0× 676 1.1× 329 1.1× 175 0.7× 143 0.7× 29 1.5k
Yann Cormerais Monaco 15 680 0.7× 392 0.6× 199 0.7× 214 0.9× 249 1.2× 20 1.0k
Joshua D. Ochocki United States 13 867 0.9× 587 0.9× 170 0.6× 221 0.9× 152 0.8× 18 1.2k
Megan D. Hoeksema United States 13 794 0.8× 552 0.9× 210 0.7× 278 1.1× 215 1.1× 13 1.2k
Fatih Ceteci Germany 14 923 0.9× 503 0.8× 413 1.4× 224 0.9× 73 0.4× 17 1.4k
Matteo Ligorio United States 4 1.0k 1.0× 1.0k 1.6× 502 1.7× 125 0.5× 165 0.8× 6 1.6k
Lynn Kirkpatrick United States 15 991 1.0× 679 1.1× 295 1.0× 179 0.7× 60 0.3× 23 1.6k
Gabriel Leprivier Germany 18 1.2k 1.2× 524 0.8× 208 0.7× 297 1.2× 64 0.3× 35 1.5k
Sharanya Sivanand United States 12 1.1k 1.2× 758 1.2× 225 0.8× 159 0.6× 95 0.5× 13 1.6k
Ibtissam Marchiq France 12 939 1.0× 756 1.2× 198 0.7× 108 0.4× 89 0.4× 16 1.3k

Countries citing papers authored by Jérôme Durivault

Since Specialization
Citations

This map shows the geographic impact of Jérôme Durivault's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Durivault with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Durivault more than expected).

Fields of papers citing papers by Jérôme Durivault

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Durivault. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Durivault. The network helps show where Jérôme Durivault may publish in the future.

Co-authorship network of co-authors of Jérôme Durivault

This figure shows the co-authorship network connecting the top 25 collaborators of Jérôme Durivault. A scholar is included among the top collaborators of Jérôme Durivault based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérôme Durivault. Jérôme Durivault is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sahu, Umakant, Julien Parola, Valérie Vial, et al.. (2025). De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma. Cancer Research. 85(10). 1857–1873. 1 indexed citations
2.
Durivault, Jérôme, Valérie Vial, Rémy Villeneuve, et al.. (2024). Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis. Current Oncology. 31(11). 7390–7402. 2 indexed citations
3.
Montemagno, Christopher, Jérôme Durivault, Maeva Dufies, et al.. (2023). A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma. Molecular Oncology. 17(7). 1379–1401. 5 indexed citations
4.
Durivault, Jérôme, Valérie Vial, Alexis Broisat, et al.. (2023). Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance. Cancer Research Communications. 3(12). 2483–2496. 5 indexed citations
5.
Pouysségur, Jacques, Ibtissam Marchiq, Scott K. Parks, et al.. (2022). ‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity – Genetic deconstruction and therapeutic perspectives. Seminars in Cancer Biology. 86(Pt 2). 334–346. 114 indexed citations
6.
Montemagno, Christopher, et al.. (2021). Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?. International Journal of Molecular Sciences. 22(12). 6413–6413. 12 indexed citations
7.
Montemagno, Christopher, Benjamín Serrano, Jérôme Durivault, et al.. (2021). In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study. Biochemistry and Biophysics Reports. 27. 101098–101098. 2 indexed citations
8.
Brachet, Etienne, Jérôme Durivault, Valérie Vial, et al.. (2021). Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma. Journal of Experimental & Clinical Cancer Research. 40(1). 33–33. 15 indexed citations
9.
Hanna, Rita, Jérôme Durivault, Fanny Burel‐Vandenbos, et al.. (2020). VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. Communications Biology. 3(1). 579–579. 12 indexed citations
10.
Daher, Boutaina, Scott K. Parks, Jérôme Durivault, et al.. (2019). Genetic Ablation of the Cystine Transporter xCT in PDAC Cells Inhibits mTORC1, Growth, Survival, and Tumor Formation via Nutrient and Oxidative Stresses. Cancer Research. 79(15). 3877–3890. 160 indexed citations
11.
Guerrini, Giuditta, Jérôme Durivault, Irene Filippi, et al.. (2019). Carbonic anhydrase XII expression is linked to suppression of Sonic hedgehog ligand expression in triple negative breast cancer cells. Biochemical and Biophysical Research Communications. 516(2). 408–413. 10 indexed citations
12.
Ndiaye, Papa Diogop, Maeva Dufies, Sandy Giuliano, et al.. (2019). VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness. Theranostics. 9(3). 661–675. 26 indexed citations
13.
Parks, Scott K., Valérie Vial, Jérôme Durivault, et al.. (2018). AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity. BMC Cancer. 18(1). 249–249. 11 indexed citations
14.
Rossin, Aurélie, et al.. (2017). The Btk-dependent PIP5K1γ lipid kinase activation by Fas counteracts FasL-induced cell death. APOPTOSIS. 22(11). 1344–1352. 5 indexed citations
15.
Cormerais, Yann, Sandy Giuliano, Renaud LeFloch, et al.. (2016). Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth. Cancer Research. 76(15). 4481–4492. 140 indexed citations
16.
Rossin, Aurélie, et al.. (2014). Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas stability. Cell Death and Differentiation. 22(4). 643–653. 66 indexed citations
17.
Pez, Floriane, Frédéric Dayan, Jérôme Durivault, et al.. (2011). The HIF-1–Inducible Lysyl Oxidase Activates HIF-1 via the Akt Pathway in a Positive Regulation Loop and Synergizes with HIF-1 in Promoting Tumor Cell Growth. Cancer Research. 71(5). 1647–1657. 131 indexed citations
18.
Grépin, Renaud, Marion Jacquin, Jérôme Durivault, et al.. (2011). Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene. 31(13). 1683–1694. 49 indexed citations
19.
Legros, Laurence, Bohrane Slama, Norbert Vey, et al.. (2011). Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Annals of Hematology. 91(1). 39–46. 8 indexed citations
20.
Pelletier, Joffrey, Frédéric Dayan, Jérôme Durivault, et al.. (2011). The asparaginyl hydroxylase factor-inhibiting HIF is essential for tumor growth through suppression of the p53–p21 axis. Oncogene. 31(24). 2989–3001. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Niantao Deng Breakdown of academic impact, for papers by Yann Cormerais Breakdown of academic impact, for papers by Joshua D. Ochocki Breakdown of academic impact, for papers by Megan D. Hoeksema Breakdown of academic impact, for papers by Fatih Ceteci Breakdown of academic impact, for papers by Matteo Ligorio Breakdown of academic impact, for papers by Lynn Kirkpatrick Breakdown of academic impact, for papers by Gabriel Leprivier Breakdown of academic impact, for papers by Sharanya Sivanand Breakdown of academic impact, for papers by Ibtissam Marchiq
Rankless by CCL
2026